Molecular diagnostics group Yourgene Health said it had restructured its financial and commercial relationship with Life Technologies. Life Technologies had exercised warrants at 9.2p per share, giving it a 9% stake in the company. It had also agreed to write off a remaining £12.7m of loans, leaving the company substantially debt free. The write off was subject to Yourgene paying a 'modest' commission on sales within Southeast Asia, up to a cap of £6.5m. Chief executive Lyan Rees said the restructure placed the company in a stronger position to capitalise on 'the significant global non-invasive prenatal testing opportunity'. At 9:48am: (LON:YGEN) share price was +0.75p at 13.75p
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.